Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6290

Provisional Schedule

Expected publication 15 May 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Novartis (tisagenlecleucel)
Others Department of Health and Social Care
  NHS England
Patient carer groups Anthony Nolan
  Blood Cancer UK
  Leukaemia Care
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies AAH Pharmaceuticals Ltd – CAU not returned, not participating
  Accord Healthcare Ltd – CAU not returned, not participating
  Alliance Healthcare Ltd – CAU not returned, not participating
  Amgen Ltd – CAU not returned, not participating
  Bristol-Myers Squibb Pharmaceutical Limited – CAU not returned, not participating
  Chugai Pharma UK Ltd – CAU not returned, not participating
  Consilient Health Ltd – CAU not returned, not participating
  Dr. Reddy's Laboratories (UK) Ltd – CAU not returned, not participating
  Esteve Pharmaceuticals Ltd – CAU not returned, not participating
  Incyte BioSciences UK Ltd – CAU not returned, not participating
  Napp Pharmaceuticals Ltd – CAU not returned, not participating
  Novartis Pharmaceuticals Ltd (imatinib)
  Pfizer Ltd – CAU not returned, not participating
  Sandoz Ltd – CAU not returned, not participating
  Sanofi – CAU not returned, not participating
  Teva Pharma B.V – CAU not returned, not participating
  Tillomed Laboratories Ltd – CAU not returned, not participating
  Viatris UK Healthcare Ltd – CAU not returned, not participating
  Zentiva Pharma Ltd – CAU not returned, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
11 April 2024 - 25 April 2024 Final draft guidance
05 March 2024 Committee meeting
04 August 2023 Invitation to participate
04 August 2023 In progress. Invitation to participate
18 July 2023 - 02 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual